HMG-CoA reductase inhibitors (statins) versus placebo for people with schizophrenia

Area of Science:

• Psychiatry and Mental Health
• Pharmacology and Therapeutics
• Clinical Research Methodology

Background:

• Schizophrenia is a complex psychiatric disorder with significant unmet treatment needs.
• Current antipsychotic treatments have limitations and side effects.
• HMG-CoA reductase inhibitors (statins) are widely used for cardiovascular disease and have immunomodulatory and neuroprotective properties that may be relevant to schizophrenia.

Purpose of the Study:

• To systematically evaluate the efficacy and safety of statins as an intervention for schizophrenia in adults.
• To compare the effects of statins with placebo in individuals diagnosed with schizophrenia.

Main Methods:

• This is a protocol for a Cochrane Review, adhering to rigorous systematic review methodology.
• The review will include randomized controlled trials comparing statins with placebo in adult schizophrenia patients.
• Data will be extracted on clinical outcomes, adverse events, and other relevant measures.

Main Results:

• This section will present the synthesized findings from included studies once the review is completed.
• Results will detail the benefits (e.g., symptom improvement) and harms (e.g., side effects) of statin use.

Conclusions:

• Conclusions will be drawn based on the synthesized evidence regarding the role of statins in schizophrenia management.
• The findings will inform clinical practice and future research directions in psychiatric pharmacotherapy.